Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Amylin Pharmaceuticals history
Amylin Pharmaceuticals company history timeline
Amylin was formed in September 1987 to develop further the amylin research of the Oxford scientists.
Amylin received its first milestone payment in August 1996, when, after reviewing data of pramlintide's development, Johnson & Johnson agreed to give Amylin $22 million and to continue with the collaboration.
The financial community took a giant step back from Amylin, causing its stock value to plummet to $.68 per share by October 1998.
In 1999, intrigued by the announcement of positive results on clinical trials of SYMLIN, the financial community renewed its interest in Amylin.
The deathblow of a drug developer had been delivered, but in October 2001, three months after EMDAC's ruling, a stunning announcement offered a lifeline.
The deal sparked new excitement in the financial community. "The fact that Joe (Cook) got a profit-sharing deal out of Eli Lilly as opposed to a royalty-based deal makes the terms much more generous for Amylin," an analyst remarked in an April 7, 2003 interview with San Diego Business Journal.
2003: Ginger Graham is appointed president and chief executive officer.
"Amylin Pharmaceuticals, Inc. ." International Directory of Company Histories. . Retrieved June 22, 2022 from Encyclopedia.com: https://www.encyclopedia.com/books/politics-and-business-magazines/amylin-pharmaceuticals-inc
Rate Amylin Pharmaceuticals' efforts to communicate its history to employees.
Amylin Pharmaceuticals jobs
Do you work at Amylin Pharmaceuticals?
Does Amylin Pharmaceuticals communicate its history to new hires?
Amylin Pharmaceuticals competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Amgen | 1980 | $33.4B | 22,000 | 535 |
| Regeneron | 1988 | $14.2B | 9,123 | 342 |
| Johnson & Johnson | 1886 | $88.8B | 134,500 | 1,716 |
| Seagen | 1997 | $2.0B | 900 | - |
| Merck | 1891 | $64.2B | 74,000 | 1,429 |
| Ariad Pharmaceuticals | 1991 | $118.8M | 380 | - |
| Human Genome Sciences | 1992 | $131.0M | 1,000 | - |
| Zoetis | 1952 | $9.3B | 11,300 | 211 |
| Gilead Sciences | 1987 | $28.8B | 11,800 | 706 |
| Baxter International | 1931 | $10.6B | 48,000 | 192 |
Amylin Pharmaceuticals history FAQs
Zippia gives an in-depth look into the details of Amylin Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Amylin Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Amylin Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Amylin Pharmaceuticals. The data presented on this page does not represent the view of Amylin Pharmaceuticals and its employees or that of Zippia.
Amylin Pharmaceuticals may also be known as or be related to Amylin Pharmaceuticals, Amylin Pharmaceuticals Inc., Amylin Pharmaceuticals LLC, Amylin Pharmaceuticals, Inc. and Amylin Pharmaceuticals, LLC.